Health Care [ 3/12 ] | Health Care Equipment & Supplies [ 27/75 ]
NASDAQ | Common Stock
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide.
The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue.
In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization.
It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors.
The company is headquartered in Alachua, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 26 | 0.07 Increased by 0.00% | 0.06 Increased by +19.45% |
| Oct 29, 25 | 0.12 Increased by +71.43% | 0.07 Increased by +71.43% |
| Aug 5, 25 | 0.12 Increased by +140.00% | 0.06 Increased by +100.00% |
| Apr 30, 25 | -0.02 Increased by +66.67% | 0.02 Decreased by -225.00% |
| Feb 25, 25 | 0.07 Increased by +216.67% | 0.03 Increased by +133.33% |
| Nov 7, 24 | 0.07 Increased by +600.00% | 0.01 Increased by +600.00% |
| Aug 8, 24 | 0.05 Increased by +266.67% | -0.04 Increased by +225.00% |
| May 2, 24 | -0.06 Increased by +40.00% | -0.07 Increased by +14.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 59.90 M Increased by +21.25% | -13.16 M Decreased by -3.02 K% | Decreased by -21.96% Decreased by -2.51 K% |
| Sep 30, 25 | 60.08 M Increased by +23.51% | 708.00 K Increased by +138.11% | Increased by +1.18% Increased by +130.85% |
| Jun 30, 25 | 56.66 M Increased by +18.26% | 579.00 K Increased by +130.14% | Increased by +1.02% Increased by +125.49% |
| Mar 31, 25 | 48.56 M Increased by +17.36% | -3.83 M Increased by +42.22% | Decreased by -7.90% Increased by +50.76% |
| Dec 31, 24 | 49.41 M Increased by +15.10% | 450.00 K Increased by +111.56% | Increased by +0.91% Increased by +110.04% |
| Sep 30, 24 | 48.64 M Increased by +17.86% | -1.86 M Increased by +54.56% | Decreased by -3.82% Increased by +61.45% |
| Jun 30, 24 | 47.91 M Increased by +25.57% | -1.92 M Increased by +71.16% | Decreased by -4.01% Increased by +77.03% |
| Mar 31, 24 | 41.38 M Increased by +12.86% | -6.63 M Increased by +6.21% | Decreased by -16.04% Increased by +16.89% |